{"nctId":"NCT01362517","briefTitle":"Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B","startDateStruct":{"date":"2010-04"},"conditions":["Diphtheria","Pertussis","Tetanus","Hepatitis B","Haemophilus Influenzae Infections"],"count":131,"armGroups":[{"label":"Quinvaxem","type":"EXPERIMENTAL","interventionNames":["Biological: Quinvaxem"]}],"interventions":[{"name":"Quinvaxem","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infants are at age of DTP vaccination of the local EPI program (60-120 days old) and free from any obvious health problems\n* Have a normal gestational age (â‰¥ 37 weeks); birth weight \\> 2.5 kg\n* There is no congenital disease detected through interview and clinical examination\n* Already had or not yet received Hepatitis B vaccination at birth\n* Do not have dermatological diseases such as eczema, allergies\n* Parent or legal guardian voluntarily provides consent for their child for participation in the study by signing the informed consent and agrees to comply with all study procedures\n\nExclusion Criteria:\n\n* Already vaccinated with DTP vaccine\n* Have an acute infection at the time of study vaccination\n* Contraindications to Quinvaxem\n* Receiving treatment with systemic corticosteroids\n* Currently participating in another clinical trial\n* In receipt of a parenteral immunoglobulin preparation and/or blood/blood products since birth\n* Parents intend to move to another location during the study (the next 12 months)","healthyVolunteers":true,"sex":"ALL","minimumAge":"60 Days","maximumAge":"120 Days","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component","description":"Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component","description":"Assessment of the proportion of subjects who have seroconverted to each of the 5 vaccine components (D, T, P, HepB, Hib)","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety: Adverse and Serious Adverse Events","description":"Assessment of the proportion of children with adverse events and/or serious adverse events following each Quinvaxem vaccine injection","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":131},"commonTop":["Pyrexia","Irritability","Injection site pain","Injection site induration","Diarrhea"]}}}